– Data Expected for Phase 2 Clinical Trial of KVD001 in Diabetic
Macular Edema Patients in the Second Half of 2019 –
– Second Oral Hereditary Angioedema Candidate Begins Phase 1 Clinical
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 5, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today an...